Showing results (221-230 of 333) with videos related to
Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, et al.Journal for Immunotherapy of Cancer|September 15, 2019
Clinical and immune profiling for cancer of unknown primary siteKoji Haratani, Hidetoshi Hayashi, Takayuki Takahama, et al.Oncotarget|October 22, 2016
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1Yoshikane Nonagase, Kimio Yonesaka, Hisato Kawakami, et al.International Journal of Cancer|January 15, 2010
Reduction of transforming growth factor-beta type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinomaHirotaka Fukasawa, Tatsuo Yamamoto, Yoshihide Fujigaki, et al.Anti-Cancer Drugs|September 25, 2020
Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective studyTakashi Kurosaki, Seiichiro Mitani, Kaoru Tanaka, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 10, 2014
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancerIsamu Okamoto, Masaki Miyazaki, Masayuki Takeda, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, et al.Future Oncology (London, England)|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.Scientific Reports|December 22, 2019
Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitorsKimio Yonesaka, Eiji Iwama, Hidetoshi Hayashi, et al.Cancer Research Communications|March 11, 2026
Constitutive EGFR activation induced by PTPRR downregulation confers resistance to KRAS inhibitorsHiroaki Kanemura, Toshiyuki Takehara, Osamu Maenishi, et al.Pageof 34